Patient and clinician perspectives on pharmacogenetic testing for antipsychotics
Among patients and clinicians who have experienced pharmacogenetic testing to inform antipsychotic prescribing, acceptability is good. There is potential for pharmacogenetics to enhance personalized prescribing, but barriers to widespread implementation remain.
Authors
- Lauren Varney (ORCID: https://orcid.org/0009-0009-1139-4790)
- Alvin Richards‐Belle (ORCID: https://orcid.org/0000-0001-8577-9380)
- Stephen Murtough (ORCID: https://orcid.org/0000-0002-7440-7095)
- Nicola J. Morant (ORCID: https://orcid.org/0000-0003-4022-8133)
- Yiran Wei (ORCID: https://orcid.org/0000-0001-7472-312X)
- Marius Cotic (ORCID: https://orcid.org/0000-0002-1481-9100)
- Noushin Saadullah Khani (ORCID: https://orcid.org/0009-0004-6678-4693)
- Rosemary Abidoph
- Elvira Bramon (ORCID: https://orcid.org/0000-0003-1369-5983)
- Daniele Panconesi (ORCID: https://orcid.org/0009-0001-1128-6687)
- Maria Richards-Brown (ORCID: https://orcid.org/0009-0001-0279-0793)
- D. R. Mills
- Beverley Chipp
Institutions
- North East London NHS Foundation Trust (GB)
- Great Ormond Street Hospital (GB)
- St Pancras Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.3389/fphar.2025.1689300
- Citations
- 2
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.56